Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Neoplasma ; 67(2): 402-409, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31847529

ABSTRACT

Angiotensin-converting enzymes, ACE and ACE2, play not only a pivotal role in the regulation of blood pressure, but are involved in the processes of pathophysiology, including thyroid dysfunction or progression of several neoplasia such as cancers of skin, lungs, pancreas and leukemia. However, their role in the thyroid carcinogenesis remains unknown. We examined in this study the expression of ACE and ACE2 in thyroid tissues and their possible employment as biomarkers for thyroid cancer progression. Thyroid tissues, including 14 goiters (G), 12 follicular adenomas (FA), 10 follicular thyroid carcinomas (FTC), 14 papillary thyroid carcinomas (PTC) and 11 undifferentiated thyroid carcinomas (UTC), were subjected to RT-PCR and protein analyses with primers or antibodies specific for ACE and ACE2, respectively. FA revealed significantly increased ACE compared to other groups and FTC was significantly higher than UTC. ACE2 was significantly increased in PTC in comparison to G, FA and UTC, and in FTC as compared to G. The ratio ACE/ACE2 decreased, while ACE2/ACE increased with the differentiation grade of thyroid carcinoma. ACE was significantly diminished in individuals older than 50. Both ACEs were significantly diminished in M1 patients, ACE2 additionally in higher tumor masses. ACE and ACE2 are regulated within thyroid benign and malignant tissues. As the transcript ratio between both enzymes correlate proportional with the differentiation status of thyroid cancer, ACE and ACE2 may serve as new markers for thyroid carcinoma.


Subject(s)
Adenocarcinoma, Follicular/genetics , Peptidyl-Dipeptidase A/genetics , Thyroid Neoplasms/genetics , Adenocarcinoma, Follicular/diagnosis , Angiotensin-Converting Enzyme 2 , Biomarkers, Tumor/genetics , Disease Progression , Humans , Thyroid Neoplasms/diagnosis
2.
Neoplasma ; 63(3): 371-7, 2016.
Article in English | MEDLINE | ID: mdl-26925783

ABSTRACT

Both adenylate-uridylate rich elements binding proteins AUF1 and HuR may participate in thyroid carcinoma progression. In this study we investigated the expression of both factors on a protein level with a special focus on follicular adenoma and follicular thyroid carcinoma. By employment of immunofluorescence and western blot on 68 thyroid tissues including 7 goiter, 16 follicular adenoma (4 adenomatous hyperplasia), 19 follicular thyroid carcinomas, 13 papillary thyroid carcinomas and 14 undifferentiated thyroid carcinomas we investigated protein expression of AUF1 and HuR. In addition to previous results we demonstrated that AUF1 and HuR are significantly up-regulated in carcinoma tissues as compared with follicular adenoma or goiter tissues. Furthermore, by evaluation of AUF1 or HuR expression, or combination of both proteins on total tissue lysates, we were able to demonstrate a significant difference between follicular adenoma and follicular thyroid carcinoma. Overexpression of AUF1 and HuR is a common finding observed in thyroid malignancy. Analysis of the tissues obtained by surgical resection as demonstrated in this study is comparable to a fine needle aspiration and in combination with AUF1/HuR immuno-analysis may support the conventional immunohistological investigations. The promising results of this study were performed on relatively small collective, but justify future development of a quick thyroid diagnostic test on larger cohort of the patients, especially for thyroid samples which are inadequate for histological examinations.


Subject(s)
Adenocarcinoma, Follicular/metabolism , Adenoma/metabolism , ELAV-Like Protein 1/biosynthesis , Heterogeneous-Nuclear Ribonucleoprotein D/biosynthesis , Thyroid Neoplasms/metabolism , Adenocarcinoma, Follicular/pathology , Adenoma/pathology , Biopsy, Fine-Needle , Blotting, Western , Fluorescent Antibody Technique , Goiter/metabolism , Goiter/pathology , Heterogeneous Nuclear Ribonucleoprotein D0 , Humans , Neoplasm Staging , Thyroid Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL